###begin article-title 0
###xml 35 41 35 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
Evaluation of the kinase domain of c-KIT in canine cutaneous mast cell tumors
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 17 23 17 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 290 296 290 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 463 469 463 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 523 529 523 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 693 699 693 699 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 172 178 <span type="species:ncbi:9606">humans</span>
###xml 243 248 <span type="species:ncbi:9606">human</span>
###xml 262 270 <span type="species:ncbi:9606">patients</span>
Mutations in the c-KIT proto-oncogene have been implicated in the progression of several neoplastic diseases, including gastrointestinal stromal tumors and mastocytosis in humans, and cutaneous mast cell tumors (MCTs) in canines. Mutations in human mastocytosis patients primarily occur in c-KIT exon 17, which encodes a portion of its kinase domain. In contrast, deletions and internal tandem duplication (ITD) mutations are found in the juxtamembrane domain of c-KIT in approximately 15% of canine MCTs. In addition, ITD c-KIT mutations are significantly associated with aberrant KIT protein localization in canine MCTs. However, some canine MCTs have aberrant KIT localization but lack ITD c-KIT mutations, suggesting that other mutations or other factors may be responsible for aberrant KIT localization in these tumors.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 91 96 91 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT</italic>
###xml 253 259 253 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 352 358 352 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 369 375 369 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 501 507 501 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 166 170 <span type="species:ncbi:9615">dogs</span>
In order to characterize the prevalence of mutations in the phospho-transferase portion of c-KIT's kinase domain in canine MCTs exons 16-20 of 33 canine MCTs from 33 dogs were amplified and sequenced. Additionally, in order to determine if mutations in c-KIT exon 17 are responsible for aberrant KIT localization in MCTs that lack juxtamembrane domain c-KIT mutations, c-KIT exon 17 was amplified and sequenced from 18 canine MCTs that showed an aberrant KIT localization pattern but did not have ITD c-KIT mutations.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
No mutations or polymorphisms were identified in exons 16-20 of any of the MCTs examined.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 63 68 63 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT</italic>
In conclusion, mutations in the phospho-transferase portion of c-KIT's kinase domain do not play an important role in the progression of canine cutaneous MCTs, or in the aberrant localization of KIT in canine MCTs.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 228 229 228 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 230 231 230 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 241 242 241 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 283 289 283 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 407 408 407 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 409 410 409 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 518 519 518 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 520 522 520 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 658 660 658 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 661 663 661 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 664 666 664 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 705 711 705 711 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 887 889 887 889 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 890 892 890 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 918 924 918 924 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 1147 1149 1147 1149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1150 1152 1150 1152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1153 1155 1153 1155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1262 1268 1262 1268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 1269 1271 1269 1271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1272 1274 1272 1274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1358 1364 1358 1364 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 1365 1367 1365 1367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1368 1370 1368 1370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1371 1373 1371 1373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1458 1464 1458 1464 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 1576 1578 1576 1578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1579 1581 1579 1581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1582 1584 1582 1584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 256 262 <span type="species:ncbi:9606">humans</span>
###xml 277 281 <span type="species:ncbi:9615">dogs</span>
###xml 672 677 <span type="species:ncbi:9606">human</span>
###xml 678 686 <span type="species:ncbi:9606">patients</span>
###xml 1030 1035 <span type="species:ncbi:9606">human</span>
###xml 1036 1044 <span type="species:ncbi:9606">patients</span>
The c-KIT proto-oncogene encodes the type III receptor tyrosine kinase KIT, which consists of an extracellular ligand binding domain, a transmembrane domain, a negative regulatory juxtamembrane domain and a split kinase domain [1-3] (Figure 1). In healthy humans as well as in dogs, c-KIT is expressed by multiple cell types including mast cells, germ cells, melanocytes, and hematopoietic precursor cells [4-8]. Notably, in mast cells KIT and its ligand stem cell factor (SCF, also known as mast cell growth factor) [9-12] have been shown to be involved in cell survival, proliferation, differentiation, chemotaxis, degranulation, and fibronectin adhesion [10,13-17]. In human patients, mutations in the c-KIT proto-oncogene have been implicated in the pathogenesis of multiple neoplastic diseases, including mastocytosis, germ cell tumors, and gastrointestinal stromal tumors (GISTs) [18-23]. The locations of these c-KIT mutations vary between the different neoplastic diseases. The vast majority of mutations characterized in human patients with mastocytosis occur at codon 816 in exon 17, which encodes a portion of the kinase domain of KIT [19,24,25]. Mutations in germ cell tumors have been found in both the juxtamembrane domain and the kinase domain of c-KIT [21,22], while mutations in GISTs tend to occur in exon 11 of the juxtamembrane domain of c-KIT [23,26,27]. Despite their variation in location both, juxtamembrane domain and kinase domains c-KIT mutations result in a constitutively activated KIT protein that is phosphorylated in the absence of the ligand [18,21-23].
###end p 11
###begin p 12
###xml 17 23 17 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 160 162 160 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 163 165 163 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 288 294 288 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 320 322 320 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 323 325 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 354 360 354 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 521 523 521 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 524 526 524 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 561 567 561 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 647 649 647 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 689 695 689 695 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 908 914 908 914 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 945 947 945 947 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 948 950 948 950 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 996 1002 996 1002 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 1167 1173 1167 1173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 1208 1210 1208 1210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1211 1213 1211 1213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 1214 1216 1214 1216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 1266 1272 1266 1272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 1346 1348 1346 1348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1495 1501 1495 1501 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 1536 1538 1536 1538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 1539 1540 1539 1540 <bold xmlns:xlink="http://www.w3.org/1999/xlink">.</bold>
###xml 154 158 <span type="species:ncbi:9615">dogs</span>
###xml 1364 1372 <span type="species:ncbi:9606">patients</span>
###xml 1435 1443 <span type="species:ncbi:9606">patients</span>
In recent years, c-KIT has been implicated in the pathogenesis of canine cutaneous mast cell tumors (MCTs), which are one of the most common neoplasms in dogs [28-32]. Internal tandem duplications (ITDs), deletions, and point mutations have been identified in the juxtamembrane domain of c-KIT in canine cutaneous MCTs [33-35]. The reported incidence of c-KIT mutations has varied between different studies. In two studies that screened randomly selected cases submitted, mutations were identified in 15% of canine MCTs [35,36]. However, another study reported c-KIT mutations in 50% of canine MCTs that were seen in a referral oncology practice [37]. This discrepancy in the incidence of c-KIT mutations in canine MCTs is most likely due to the variations in case selection between these studies with the higher percentage reflecting ascertainment bias at the referral practice. Internal tandem duplication c-KIT mutations are the most common [35,38], and therefore the most extensively studied c-KIT mutation in canine MCTs. All of the ITD mutations that have been studied thus far have been found to produce a constitutively activated product, thereby implicating c-KIT in the progression of canine MCTs [33,34,39]. Previous work by our laboratory has shown that c-KIT mutations are significantly associated with higher histologic grade MCTs [35], and that MCT patients with ITDs have a significantly worse prognosis as compared to patients without ITD mutations, thereby further implicating c-KIT in the progression of canine MCTs [36].
###end p 12
###begin p 13
###xml 15 21 15 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 157 159 157 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 160 162 160 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 454 455 454 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 784 786 784 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 825 831 825 831 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 1050 1052 1050 1052 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 1109 1115 1109 1115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
In addition to c-KIT mutations, aberrant KIT expression and more specifically, the aberrant localization of KIT has been described in canine cutaneous MCTs [40-42]. Recently our laboratory has identified 3 patterns of KIT protein localization in canine MCTs: 1. peri-membrane KIT localization (KIT pattern 1); 2. cytoplasmic stippling to focal KIT localization (KIT pattern 2); 3. diffuse cytoplasmic KIT localization (KIT pattern 3), as shown in Figure 2. Recent studies have shown that canine MCTs that have a primarily cytoplasmic pattern of KIT protein localization (KIT patterns 2 and 3) have a significantly worse prognosis, in terms of both their disease-free interval and survival duration, as compared to MCTs that have a primarily peri-membrane pattern of KIT localization [41]. Furthermore, we have found that ITD c-KIT mutations in canine MCTs are significantly associated with aberrant KIT localization in neoplastic mast cells. However, a substantial number of canine MCTs have aberrant KIT localization, but do not have ITD mutations [36]. This suggests that additional factors, aside from ITD c-KIT mutations may be responsible for aberrant KIT localization in neoplastic mast cells.
###end p 13
###begin p 14
###xml 30 36 30 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 207 213 207 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 214 216 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 217 219 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 265 271 265 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 394 400 394 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 533 538 533 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT</italic>
###xml 735 741 735 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 63 68 <span type="species:ncbi:9606">human</span>
###xml 69 77 <span type="species:ncbi:9606">patients</span>
###xml 581 586 <span type="species:ncbi:9606">human</span>
###xml 600 608 <span type="species:ncbi:9606">patients</span>
Despite the high incidence of c-KIT kinase domain mutations in human patients with mastocytosis, only a total of 18 canine MCTs and 3 canine MCT cell lines have been evaluated for kinase domain mutations in c-KIT [33,34]. For a more detailed evaluation of possible c-KIT kinase domain mutations in canine MCTs, we screened exons 16-20 of the phospho-transferase portion of the kinase domain of c-KIT for mutations that may contribute to the progression of these tumors. Additionally, in order to determine if mutations in exon 17 of c-KIT, where the majority of mutations occur in human mastocytosis patients, were responsible for aberrant KIT localization, exon 17 was screened in 18 MCTs with aberrant KIT localization that lack ITD c-KIT mutations. However, no mutations or polymorphisms were identified in exons 16-20 of any of the canine MCTs that were examined.
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
Study population
###end title 16
###begin p 17
###xml 396 398 396 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 46 50 <span type="species:ncbi:9615">dogs</span>
Samples from 33 canine cutaneous MCTs from 33 dogs were obtained from archival formalin-fixed paraffin-embedded tissues that had been submitted to the Diagnostic Center for Population and Animal Health at Michigan State University. Single paraffin blocks with neoplastic tissue were selected for each tumor and each tumor was histologically graded based on the Patnaik histologic grading system [43] for canine cutaneous MCTs.
###end p 17
###begin title 18
DNA isolation from formalin-fixed paraffin embedded tissues
###end title 18
###begin p 19
###xml 134 136 134 136 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3 </sup>
###xml 243 245 243 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 246 248 246 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
Tissue samples for DNA isolation were selected within the tumor boundaries, as identified by histologic evaluation. Approximately 2 mm3 tissue samples were obtained from each block for DNA extraction. DNA was isolated as previously described [35,44]. In brief, 400 mul of digestion buffer (50 mM Tris, pH 8.5, 1 mM EDTA, 0.5% Tween) was added to each sample. Samples were heated to 95degreesC for 10 minutes followed by heating in a microwave at full power twice for 30 seconds. Samples were thoroughly vortexed between each heating step. 5 mul of 15 mg/ml proteinase K was added to each sample, and the samples were subsequently incubated overnight at 42degreesC. Proteinase K was inactivated at 95degreesC for 10 minutes. Samples were then centrifuged and 200 mul of the reaction was aliquoted for use as template in PCR.
###end p 19
###begin title 20
Amplification of c-KIT exons 16-20
###end title 20
###begin p 21
###xml 196 197 196 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 206 207 206 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 426 427 424 425 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
PCR amplification was carried out using primer pairs that flanked exons 16, 17, 18, 19, and 20 in order to sequence each exon in its entirety and the 10-20 nucleotides that flank each exon (Table 1, Figure 3). Twenty-five microliter PCR reactions were prepared with 5 mul DNA at a 1:25 dilution, 5 pmol of each primer, 0.5 units of Taq polymerase (Invitrogen, Carlsbad, CA), and final concentrations of 80 muM dNTPs, 2 mM MgCl2, 20 mM Tris-HCl, and 50 mul KCl. Cycling conditions for amplifying exons 16, 17, 18, and 20 were as follows: 94degreesC for 4 minutes; 40 cycles at 94degreesC for 1 minute, 60degreesCfor 1 minute, and 72degreesC for 1 minute; 72degreesC for 5 minutes. Cycling conditionswere similar for exon 19, except a 54degreesC annealing temperature was used instead of a 60degreesC annealing temperature. Amplified products were visualized by agarose gel electrophoresis on a 2% agarose gel stained with ethidium bromide.
###end p 21
###begin title 22
Sequencing of c-KIT exons 16-20
###end title 22
###begin p 23
###xml 112 114 112 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
Amplified products were pooled in groups of 7-10 for DNA sequencing whenever possible, as previously described [45]. This pool and sequence method has been shown to allow for the detection of minor alleles at frequencies as low as 5%. If clean sequences were not obtained from pooled samples, then samples were sequenced individually. DNA to be sequenced was separated on a 2% agarose gel, and DNA fragments were excised for DNA purification. DNA was purified using the Qiaex II gel purification kit (Qiagen, Valencia, CA) according to manufacturer's protocol. DNA sequencing was carried out using the Thermo Sequenase radiolabeled terminator cycle sequencing kit (Amersham, Piscataway, NJ), following manufacturer's instruction. Sequence reactions were separated on a 6% denaturing polyacrylamide gel, which was dried and exposed to BioMax MR scientific imaging film (Kodak, Rochester, NY) for 72 hours for visualization.
###end p 23
###begin title 24
DNA isolation from laser capture microdissected tumor samples
###end title 24
###begin p 25
###xml 57 63 57 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 118 120 118 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 847 853 831 837 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
Eighteen MCTs with aberrant KIT localization, but no ITD c-KIT mutations were identified as part of a previous study [36] (figure 3. Seven micron sections of each MCT were dehydrated and stained with hematoxylin for laser capture microdissection. 2,000-4,000 neoplastic mast cells were extracted from each tumor sample using the Pixcell laser capture microdissection system with Macro LCM caps (Arcturus, Mountain View, CA). LCM caps adhered to extracted cells were incubated inverted overnight in 50 mul of DNA extraction buffer (10 mM Tris pH 8.0, 1 mM EDTA, 1% Tween) and 1.5 mul of 15 mg/ml Proteinase K at 37degreesC. Samples were centrifuged at 1306 x g for 5 minutes, and Proteinase K was inactivated by heating at 95degreesC for 8 minutes. 5 mul of DNA was used for each 25 mul reaction. PCR reactions were prepared using primers flanking c-KIT exon 17 as described above.
###end p 25
###begin title 26
Results
###end title 26
###begin p 27
###xml 480 482 480 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 674 679 674 679 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT</italic>
###xml 773 779 773 779 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 36 40 <span type="species:ncbi:9615">dogs</span>
###xml 87 91 <span type="species:ncbi:9615">dogs</span>
###xml 165 169 <span type="species:ncbi:9615">dogs</span>
###xml 363 367 <span type="species:ncbi:9615">dogs</span>
Thirty-three cutaneous MCTs from 33 dogs were included in this study. The age of these dogs ranged from 2.5-15 years with an average of 7.42 years. Twenty of the 33 dogs were female and 13 were male. The breed distribution of this study population included 10 boxers, 9 Labrador retrievers, 5 golden retrievers, 1 Boston terrier, 1 Bichon Frise and 7 mixed breed dogs. All MCTs were graded according to the Patnaik histologic grading system for canine cutaneous mast cell tumors [43]. Twelve of the 33 MCTs were histologic grade 1, 18 were grade 2, and 3 were grade 3. All 33 MCTs included in this study were previously screened for mutations in the juxtamembrane domain of c-KIT. No internal tandem duplications or deletions were identified in the juxtamembrane domain of c-KIT in any of the MCTs included in this study (data not shown).
###end p 27
###begin p 28
###xml 52 58 52 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 310 316 310 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 410 416 410 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 535 538 535 538 <sup xmlns:xlink="http://www.w3.org/1999/xlink">th </sup>
In order to identify potential activating mutations c-KIT exons 16, 17, 18, 19, and 20, which encode the phospho-transferase region of the kinase domain of the KIT protein, were amplified using PCR amplification and sequenced. Exons 16 to 20 were identical to previously published cDNA sequences of the canine c-KIT gene [Genbank:] in all canine MCTs examined. No mutations or polymorphisms were identified in c-KIT exons 16 to 20 in any of the canine cutaneous MCTs screened. One single nucleotide polymorphism was identified at the 7th nucleotide of intron 18 consisting of a C to A transversion.
###end p 28
###begin p 29
###xml 73 79 73 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 262 268 262 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 279 281 279 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 329 335 329 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 365 367 365 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 368 370 368 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 371 373 371 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 426 432 426 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 515 521 515 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 634 640 634 640 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 287 292 <span type="species:ncbi:9606">human</span>
###xml 306 314 <span type="species:ncbi:9606">patients</span>
Previous work by our laboratory has identified a correlation between ITD c-KIT mutations and aberrant KIT localization in canine cutaneous MCTs. However, we have also found that a subset of canine cutaneous MCTs have aberrant KIT localization without having ITD c-KIT mutations [36]. In human mastocytosis patients, mutations of c-KIT are commonly seen in exon 17 [19,24,25]. In order to test the hypothesis that mutations in c-KIT exon 17 are responsible for aberrant KIT localization in canine MCTs that lack ITD c-KIT mutations, exon 17 was amplified and sequenced from 18 such cases. Exon 17 was identical to previously published c-KIT sequences [Genbank:] and no mutations or polymorphisms were identified in exon 17 in any of the canine MCTs evaluated.
###end p 29
###begin title 30
Discussion
###end title 30
###begin p 31
###xml 79 85 79 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 247 249 247 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 324 330 324 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 419 425 419 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 517 519 517 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 520 522 520 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 523 525 523 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 483 488 <span type="species:ncbi:9606">human</span>
###xml 489 497 <span type="species:ncbi:9606">patients</span>
This study did not identify any mutations of the phospho-transferase domain of c-KIT in 33 canine cutaneous MCTs examined. These findings are also supported by reports from London et al. in which 11 MCTs were examined for kinase domain mutations [33]. Therefore, it is highly unlikely that the phospho-transferase domain of c-KIT plays a role in the progression of canine MCTs. Furthermore, mutations in exon 17 of the c-KIT proto-oncogene, where mutations are most commonly seen in human patients with mastocytosis [19,24,25], do not contribute to the aberrant localization of KIT in canine cutaneous MCTs.
###end p 31
###begin p 32
###xml 21 27 21 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 382 383 382 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 720 726 720 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 55 61 <span type="species:ncbi:9606">humans</span>
###xml 98 103 <span type="species:ncbi:9606">human</span>
###xml 252 257 <span type="species:ncbi:9606">human</span>
###xml 314 317 <span type="species:ncbi:9615">dog</span>
###xml 430 435 <span type="species:ncbi:9606">human</span>
###xml 444 447 <span type="species:ncbi:9615">dog</span>
###xml 632 637 <span type="species:ncbi:9606">human</span>
###xml 651 659 <span type="species:ncbi:9606">patients</span>
###xml 677 682 <span type="species:ncbi:9606">human</span>
###xml 696 704 <span type="species:ncbi:9606">patients</span>
The kinase domain of c-KIT is highly conserved between humans and canines. In a comparison of the human [Genbank: ] and canine [Genbank: ] amino acid sequences corresponding to exons 16-20, there is only a single difference in which a glutamate in the human is replaced with an aspartate residue in exon 20 of the dog, giving greater than 99% identity between these species (figure 4). The high degree of conservation between the human and the dog suggests that a change in a single amino acid of the kinase domain could alter the function of the KIT protein, potentially producing a constitutively activated protein, as is seen in human mastocytosis patients. However, unlike human mastocytosis patients, kinase domain c-KIT mutations do not appear to play a role in the progression of canine MCTs.
###end p 32
###begin p 33
###xml 74 80 74 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 138 140 138 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 230 236 230 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 262 264 262 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 265 267 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 468 470 468 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 471 473 471 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 474 476 474 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 503 509 503 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 550 552 550 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 553 555 553 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 588 594 588 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 671 673 671 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 676 682 676 682 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 744 746 744 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 760 766 760 766 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 843 845 843 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 846 848 846 848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 849 851 849 851 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 852 854 852 854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 855 857 855 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 665 669 <span type="species:ncbi:9615">dogs</span>
Internal tandem duplications and deletions in the juxtamembrane domain of c-KIT have been identified in approximately 15% of canine MCTs [36]. The internal tandem duplication mutations are the most frequent and best characterized c-KIT mutations in canine MCTs [35,38]. All of the characterized ITD mutations result in a constitutively activated KIT product, which is characterized by the constitutive phosphorylation of the receptor in the absence of ligand binding [33,34,39]. Considering the role of c-KIT in mast cell survival and proliferation [10,17]and the association between ITD c-KIT mutations and decreased disease-free interval and survival duration of dogs [36], c-KIT appears to play a key role in the progression of canine MCTs [36]. Therefore, c-KIT may also represent a potential therapeutic target for canine cutaneous MCTs [35-37,39,41,46].
###end p 33
###begin p 34
###xml 21 27 21 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 99 101 99 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 102 104 102 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 187 193 187 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 277 283 277 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 418 424 418 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 479 485 479 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 745 747 745 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 748 750 748 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 751 753 751 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 769 775 769 775 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 1052 1058 1052 1058 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 1104 1110 1104 1110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 1382 1384 1382 1384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 1421 1423 1421 1423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 1424 1426 1424 1426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 1427 1429 1427 1429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 1335 1340 <span type="species:ncbi:9606">human</span>
###xml 1372 1380 <span type="species:ncbi:9606">patients</span>
###xml 1400 1405 <span type="species:ncbi:9606">human</span>
###xml 1411 1419 <span type="species:ncbi:9606">patients</span>
Juxtamembrane domain c-KIT mutations have only been found in approximately 15% of all canine MCTs [35,36] and 50% of high grade MCTs [37]. We hypothesized that phospho-transferase domain c-KIT mutations may play a role in the progression of canine cutaneous MCTs that lack ITD c-KIT mutations. The goal of this study was to investigate the presence of any activating mutations in the phospho-transferase domain of the c-KIT proto-oncogene. The results of this study suggest that c-KIT mutations of the phospho-transferase domain do not play a significant role in the progression of canine MCTs. Since some small molecule kinase inhibitors have shown a greater efficacy in tumors with mutations in the target receptor tyrosine kinase (e.g. KIT) [39,47,48], MCTs lacking c-KIT mutations may not be as good of candidates for the treatment with these drugs. Therefore, other genetic or epigenetic changes that play a role in the progression of canine MCTs need to be identified in order to develop targeted treatment strategies in those MCTs that lack ITD c-KIT mutations. However, additional domains of the c-KIT proto-oncogene still need to be evaluated for the presence of activating mutations in canine MCTs. One area of particular interest is, the extracellular ligand-binding domain where mutations have been identified in exon 8 of human familial mastocytosis and GIST patients [49] and exon 9 of human GIST patients [48,50,51].
###end p 34
###begin p 35
###xml 72 78 72 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 141 143 141 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 177 183 177 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 451 457 451 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 468 470 468 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 528 534 528 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 679 685 679 685 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 767 773 767 773 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 892 897 892 897 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT</italic>
###xml 926 932 926 932 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 575 580 <span type="species:ncbi:9606">human</span>
###xml 581 589 <span type="species:ncbi:9606">patients</span>
Additional work from our laboratory has shown a correlation between ITD c-KIT mutations and the aberrant localization of KIT in canine MCTs [36]. These results suggest that ITD c-KIT mutations may lead to the aberrant cytoplasmic localization of KIT in at least a subset of canine MCTs. Despite this correlation between ITD mutations and aberrant KIT localization, we have identified some MCTs that have aberrant KIT localization, but do not have ITD c-KIT mutations [36]. We hypothesized that point mutations in exon 17 of the c-KIT proto-oncogene, similar to those seen in human patients with mastocytosis, are responsible for the aberrant KIT localization in MCTs without ITD c-KIT mutations. However, in this study we did not find any mutations in exon 17 of the c-KIT proto-oncogene in 18 canine cutaneous MCTs with aberrant KIT localization. These results suggest that other changes to c-KIT, such as mutations in other c-KIT domains, changes in transcriptional regulation or alternative splicing, or other cellular changes, such as changes in golgi processing or intracellular trafficking may be responsible for aberrant KIT localization and may therefore play a role in the progression of canine cutaneous MCTs.
###end p 35
###begin title 36
Conclusion
###end title 36
###begin p 37
###xml 31 37 31 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 240 246 240 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 378 384 378 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 455 461 455 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 790 792 790 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 793 795 793 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 925 931 925 931 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 1195 1201 1195 1201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
In this study no kinase domain c-KIT mutations were found in any canine cutaneous MCT examined and therefore these mutations do not appear to play a significant role in the progression of this disease. In accordance with this data, exon 17 c-KIT mutations do not appear to be responsible for aberrant KIT localization in canine MCTs with aberrant KIT localization that lack ITD c-KIT mutations. Due to the relatively low incidence of juxtamembrane domain c-KIT mutations, and the lack of kinase domain mutations in canine cutaneous MCTs, further studies are necessary to identify additional factors and genes that lead to the progression of canine cutaneous MCTs. Although targeting constitutively activated KIT protein in canine MCTs offers great promise for the treatment of canine MCTs [39,46], such a therapeutic approach may not be justified for all MCTs. A significant number of MCTs seem to have no alterations in the c-KIT proto-oncogene, and targeted inhibition of this gene will therefore have little or no effect on these tumors. Therefore, additional studies need to be performed in order to determine other factors that may be involved in the progression of canine MCTs without ITD c-KIT mutations in order to identify potential targets in those tumors.
###end p 37
###begin title 38
Competing interests
###end title 38
###begin p 39
The author(s) declare that they have no competing interests.
###end p 39
###begin title 40
Authors' contributions
###end title 40
###begin p 41
JDW carried out the PCR amplification and sequencing of this study, with technical assistance from Daniel Zemke, Elizabeth Kruszewski, and Angela Sosin, and drafted the manuscript.
###end p 41
###begin p 42
MK participated in the design of the study and helped draft the manuscript.
###end p 42
###begin p 43
VYG participated in the design of the study, coordinated the study and helped draft the manuscript.
###end p 43
###begin p 44
All authors red and approved the final manuscript.
###end p 44
###begin title 45
Pre-publication history
###end title 45
###begin p 46
The pre-publication history for this paper can be accessed here:
###end p 46
###begin p 47

###end p 47
###begin title 48
Acknowledgements
###end title 48
###begin p 49
The authors would like to acknowledge Dr. Daniel Zemke, Elizabeth Kruszewski, and Angela Sosin for their technical assistance. Funding for this study was provided in part by the Companion Animal Fund of the College of Veterinary Medicine, Michigan State University. JDW is funded by NIH T-32 post-doctoral training grant number RR17189.
###end p 49
###begin article-title 50
Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors
###end article-title 50
###begin article-title 51
###xml 21 26 21 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-kit</italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand
###end article-title 51
###begin article-title 52
Autoinhibition of the KIT receptor tyrosine kinase by cystolic juxtamembrane region
###end article-title 52
###begin article-title 53
###xml 14 20 14 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-kit </italic>
###xml 98 102 <span type="species:ncbi:10090">mice</span>
###xml 152 156 <span type="species:ncbi:10090">mice</span>
Expression of c-kit gene products in known cellular targets of W mutations in normal and W mutant mice- evidence for an impaired c-kit kinase in mutant mice
###end article-title 53
###begin article-title 54
###xml 14 20 14 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-kit </italic>
###xml 55 60 <span type="species:ncbi:9606">human</span>
Expression of c-kit receptor in normal and transformed human nonlymphoid tissues
###end article-title 54
###begin article-title 55
###xml 18 24 18 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-kit </italic>
###xml 35 40 <span type="species:ncbi:9606">human</span>
Expression of the c-kit protein in human solid tumors and in corresponding fetal and adult normal tissues
###end article-title 55
###begin article-title 56
###xml 171 177 <span type="species:ncbi:9606">humans</span>
Preferential localization of c-kit product in tissue mast cells, basal cells of skin, epithelial cells of breast, small cell lung carcinoma, and seminomas/dysgerminoma in humans: immunohistochemical study on formalin-fixed, paraffin-embedded tissues
###end article-title 56
###begin article-title 57
###xml 34 40 34 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-kit </italic>
###xml 64 69 <span type="species:ncbi:9606">human</span>
Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the dagnosis of mast cell disorders
###end article-title 57
###begin article-title 58
###xml 87 93 87 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-kit </italic>
The hematopoietic growth factor KL is encoded by the Sl locus and is the ligand of the c-kit receptor, the gene product of the W locus
###end article-title 58
###begin article-title 59
###xml 24 30 24 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-kit </italic>
Canidate ligand for the c-kit transmembrane kinase receptor: KL, a fibroblast derived growth factor stimulates mast cells and erythroid progenitors
###end article-title 59
###begin article-title 60
###xml 106 109 <span type="species:ncbi:10116">rat</span>
Identification, purification, and biological characterization of hematopoietic stem cell factor from bull rat liver-conditioned medium
###end article-title 60
###begin article-title 61
###xml 83 89 83 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-kit </italic>
###xml 51 56 <span type="species:ncbi:10090">mouse</span>
Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor
###end article-title 61
###begin article-title 62
###xml 82 88 82 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-kit </italic>
###xml 78 81 <span type="species:ncbi:10116">rat</span>
Induction of mast cell proliferation, maturation and heparin synthesis by the rat c-kit ligand, stem cell factor
###end article-title 62
###begin article-title 63
###xml 22 28 22 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-kit </italic>
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 82 87 <span type="species:ncbi:9606">human</span>
The human recombinant c-kit receptor ligand, rhSCF, induces mediator release from human cutaneous mast cells and enhances IgE-dependent mediator release from both skin mast cells and peripheral blood basophils
###end article-title 63
###begin article-title 64
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-kit </italic>
The c-kit receptor ligand functions as a mast cell chemoattractant
###end article-title 64
###begin article-title 65
Stem cell factor induces mast cell adhesion to fibronectin
###end article-title 65
###begin article-title 66
###xml 142 146 <span type="species:ncbi:10090">mice</span>
Role of kit-ligand in proliferation and suppression of apoptosis in mast cells: basis for radiosensitivity of white spotting and steel mutant mice
###end article-title 66
###begin article-title 67
###xml 73 79 73 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-kit </italic>
###xml 84 89 <span type="species:ncbi:9606">human</span>
Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product
###end article-title 67
###begin article-title 68
###xml 77 83 77 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-kit </italic>
###xml 124 132 <span type="species:ncbi:9606">patients</span>
Identification of a point mutation in the catalytic domain of proto-oncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder
###end article-title 68
###begin article-title 69
###xml 8 14 8 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-kit </italic>
###xml 119 124 <span type="species:ncbi:9606">human</span>
Somatic c-kit activating mutation in utricaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm
###end article-title 69
###begin article-title 70
###xml 11 17 11 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-kit </italic>
###xml 35 40 <span type="species:ncbi:9606">human</span>
Activating c-kit gene mutations in human germ cell tumors
###end article-title 70
###begin article-title 71
###xml 19 25 19 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-kit </italic>
Alterations of the c-kit gene in testicular germ cell tumors
###end article-title 71
###begin article-title 72
###xml 30 36 30 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-kit </italic>
###xml 39 44 <span type="species:ncbi:9606">human</span>
Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors
###end article-title 72
###begin article-title 73
###xml 49 55 49 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-kit </italic>
###xml 109 117 <span type="species:ncbi:9606">patients</span>
Clinical correlates of the presence of Asp816Val c-kit mutation in the peripheral blood mononuclear cells of patients with mastocytosis
###end article-title 73
###begin article-title 74
###xml 37 43 37 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-kit </italic>
###xml 100 105 <span type="species:ncbi:9606">human</span>
Activating and dominant inactivating c-kit catalytic domain mutations in distinct clinical forms of human mastocytosis
###end article-title 74
###begin article-title 75
###xml 24 30 24 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-kit </italic>
Mutations in exon 11 of c-kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leioyosarcomas
###end article-title 75
###begin article-title 76
###xml 10 16 10 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-kit </italic>
Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors
###end article-title 76
###begin article-title 77
Canine and feline neoplasia
###end article-title 77
###begin article-title 78
Skin tumors in domestic animals. Data from 12 United States and Canadian colleges of veterinary medicine
###end article-title 78
###begin article-title 79
###xml 18 22 <span type="species:ncbi:9615">dogs</span>
Skin neoplasia in dogs
###end article-title 79
###begin article-title 80
###xml 18 22 <span type="species:ncbi:9615">dogs</span>
Skin neoplasms of dogs in Sydney
###end article-title 80
###begin article-title 81
Mast cells and canine mast cell tumors: a review
###end article-title 81
###begin article-title 82
Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene
###end article-title 82
###begin article-title 83
###xml 38 44 38 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
Clustering of activating mutations in c-KIT 's juxtamembrane coding region in canine mast cell neoplasms
###end article-title 83
###begin article-title 84
###xml 41 47 41 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 100 104 <span type="species:ncbi:9615">dogs</span>
Mutations in the juxtamembrane domain of c-KIT are associated with higher grade mast cell tumors in dogs
###end article-title 84
###begin article-title 85
###xml 12 18 12 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
The role of c-KIT in tumorigenesis:evaluation in canine cutaneous mast cell tumors
###end article-title 85
###begin article-title 86
###xml 80 86 80 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 109 113 <span type="species:ncbi:9615">dogs</span>
Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-KIT in mast cell tumors of dogs
###end article-title 86
###begin article-title 87
###xml 13 19 13 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
Detection of c-KIT mutations in canine mast cell tumors using fluorescent polyacrylamide gel electrophoresis
###end article-title 87
###begin article-title 88
Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors
###end article-title 88
###begin article-title 89
Canine mast cell tumors express stem cell factor receptor
###end article-title 89
###begin article-title 90
The use of KIT and tryptase expression patterns as prognostic tools for canine cutaneous mast cell tumors
###end article-title 90
###begin article-title 91
###xml 83 86 <span type="species:ncbi:9615">dog</span>
Expression of the KIT protein (CD117) in primary cutaneous mast cell tumors of the dog
###end article-title 91
###begin article-title 92
###xml 78 82 <span type="species:ncbi:9615">dogs</span>
Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs
###end article-title 92
###begin article-title 93
Microwave-based DNA extraction from paraffin-embedded tissue for PCR amplification
###end article-title 93
###begin article-title 94
###xml 36 40 <span type="species:ncbi:9615">dogs</span>
Estimate of nucleotide diversity in dogs with a pool-and -sequence method
###end article-title 94
###begin article-title 95
Inhibition of constitutively active forms of mutant KIT by multitargeted indolinone tyrosine kinase inhibitors
###end article-title 95
###begin article-title 96
###xml 7 13 7 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 88 96 <span type="species:ncbi:9606">patients</span>
Use of c-KIT /PDGFR mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group
###end article-title 96
###begin article-title 97
###xml 42 50 <span type="species:ncbi:9606">patients</span>
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor
###end article-title 97
###begin article-title 98
Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis
###end article-title 98
###begin article-title 99
KIT activation is a ubiquitous feature in gastrointestinal stromal tumors
###end article-title 99
###begin article-title 100
The location of KIT and PDGFRA gene mutations in gastrointestinal stromal tumours is site and phenotype associated
###end article-title 100
###begin title 101
Figures and Tables
###end title 101
###begin p 102
Schematic diagram of the receptor tyrosine kinase KIT.
###end p 102
###begin p 103
###xml 376 382 376 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 423 429 423 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
###xml 501 507 501 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
Immunohistochemical staining patterns of canine cutaneous MCTs staining with anti-KIT antibodies. A. KIT staining pattern 1: peri-membrane KIT protein localization; B. KIT staining pattern 2: focal or stippled cytoplasmic KIT protein localization; C. KIT staining pattern 3: Diffuse cytoplasmic KIT localization. Canine MCTs with KIT staining patterns 2 and 3 that lacked ITD c-KIT mutations were screened for mutations in c-KIT exon 17. B and C show MCTs with aberrant KIT localization that lack ITD c-KIT mutations.
###end p 103
###begin p 104
Schematic Diagram of Primer Design for Polymerase Chain Reaction. Forward and reverse primers (arrows) were designed in introns (black boxes) flanking exons 16, 17, 18, 19, and 20 (white boxes).
###end p 104
###begin p 105
###xml 70 75 <span type="species:ncbi:9606">human</span>
###xml 92 97 <span type="species:ncbi:9606">human</span>
###xml 268 273 <span type="species:ncbi:9606">human</span>
###xml 287 295 <span type="species:ncbi:9606">patients</span>
Amino acid alignment of the kinase domain (exons 16-20) of canine and human KIT. Canine and human amino acid alignments demonstrate a 99.5% identity between the phospho-transferase portion of the kinase domain of these species. Codon 816, which is commonly mutated in human mastocytosis patients (D816V; shaded residue) is also conserved in canine KIT.
###end p 105
###begin p 106
###xml 38 44 38 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-KIT </italic>
Primers used for PCR amplification of c-KIT exons 16-20 and size of expected PCR products for each primer pair.
###end p 106

